ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/31/19

- Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio - - Caelum to receive up to $60 million for equity investment and option fee - - Alexion has option to acquire Caelum based on Phase 2 data - Alexion Pharmaceuticals,...

Fortress-founded Caelum Biosciences to receive $60 million in a strategic equity investment and option fee Alexion has option to acquire Caelum Biosciences based on Phase 2 data NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortressȁ...

During its Q4 earnings call, Amgen ( AMGN -5.2% ) chief Bob Bradway said his company is maintaining its attention on potential acquisitions, large and small, that represent reasonable valuations for expected growth, adding that the organization has the resources to make things happen. ...

A Phase 3 clinical trial evaluating Alexion Pharmaceuticals' (NASDAQ: ALXN ) ULTOMIRIS (ravulizumab-cwvz) (formerly ALXN1210) in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS) met the primary endpoint of complete thrombotic microangiopathy (TMA) r...

-- Study met primary objective of complete thrombotic microangiopathy (TMA) response -- -- Regulatory submission in the U.S. planned for first half of 2019, followed by the European Union and Japan -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 ...

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cigna Corporation (NYSE:CI), Alexion Pharmaceuticals, Inc. (NASDAQ:ALX...